Beauty Industry Mergers Enter a New, Price-Driven Era
Beauty industry mergers are large-scale transactions where cosmetics, skincare, and fragrance groups buy or combine with other brands to gain growth, market reach, and category strength, but recent deals show that valuation discipline now matters as much as strategic fit. The abandoned Estée Lauder acquisition talks with Puig highlight how pricing disagreements can derail even well-aligned cosmetics M&A deals. Estée Lauder’s leadership has been clear that growth and profitability must line up with “the right price point” before it will commit to another large transaction. At the same time, consolidation is still moving ahead through more selective portfolio moves. Waldencast’s decision to sell Obagi Medical and focus on Milk Makeup shows a different side of beauty consolidation strategy: reshaping existing portfolios instead of chasing mega-mergers at any price.
Inside Estée Lauder’s Puig Breakdown: Strategy Yes, Valuation No
Estée Lauder and Puig ended merger talks after failing to agree on valuation, even though a combination was widely seen as strategically logical within beauty industry mergers. Media reports suggested the merged group could have been worth around USD 40 billion (approx. RM184 billion), but neither side confirmed the figure. Speaking at a Deutsche Bank consumer conference, Estée Lauder’s Stephane de La Faverie said the talks collapsed because the deal was “not at the right price,” underscoring a tougher stance on capital allocation in cosmetics M&A deals. Puig’s chairman Marc Puig echoed that economic terms must “appropriately value the company and are fair to all stakeholders.” Rather than signaling retreat, Estée Lauder has said it remains open to future Estée Lauder acquisition opportunities that fit its “Beauty Reimagined” strategy and deliver growth without overpaying.
Waldencast’s Obagi Sale: Portfolio Focus Over Empire Building
While mega-mergers struggle on price, other players are slimming down to sharpen their beauty consolidation strategy. Waldencast agreed to sell Obagi Medical to private equity firm Bridgepoint for USD 460 million (approx. RM2.1 billion), a move that will leave it focused on its colour cosmetics and skincare brand Milk Makeup. Waldencast, launched as a SPAC in 2021, had created a USD 1.2 billion (approx. RM5.5 billion) platform when it acquired Obagi Medical and Milk Makeup in 2022, but a strategic review led to a change in direction. Co-founders Michel Brousset and Hind Sebti will exit Waldencast to lead Obagi Medical alongside Bridgepoint, while Milk Makeup’s president Mazdack Rassi continues to steer the remaining business. According to Waldencast’s board, the Obagi sale strengthens the balance sheet and supports a clearer, single-brand growth plan.
From Empire Chasing to Precision Buying in Cosmetics M&A Deals
Both Estée Lauder and Waldencast show how beauty industry mergers are shifting from empire building to precision buying and selling. Estée Lauder is reportedly reviewing options for brands such as Too Faced, Smashbox, and Dr. Jart+, suggesting it may prune parts of its portfolio even as it remains interested in new acquisitions. Waldencast’s divestiture of Obagi Medical and its intention to repay all outstanding senior term loans highlight how financial health and focus increasingly guide strategy. In this new environment, price-sensitive cosmetics M&A deals are being judged not only on revenue potential but also on cost savings, balance-sheet impact, and clear brand roles. Beauty consolidation strategy is migrating toward fewer, better-aligned assets rather than sprawling stables assembled at high valuations.
